Rapport Therapeutics, Inc. (RAPP) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 38 days, typically, give or take 15 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Wed, Nov 4, 2026before open 35 8-K
Q2 FY2026Wed, Aug 5, 2026before open 36 8-K
Q1 FY2026Thu, May 7, 2026before open 37 8-K
Q4 FY2025Tue, Mar 10, 2026before open 69 8-K
Q3 FY2025Thu, Nov 6, 2025before open 37 8-K
Q2 FY2025Thu, Aug 7, 2025before open 38 8-K
Q1 FY2025Thu, May 8, 2025before open 38 8-K
Q4 FY2024Tue, Mar 11, 2025before open 70 8-K

What they guided beta

Q3 FY2026 "Exhibit 99.1 Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027 Data from the Phase 2 FOS open-label long-term safety trial expected in 4Q 2026; Phase 3 FOS trials enrolling patients Well-capitalized with $815.4 million 1 in cash and cash equivalents as of November 3, 2026, and runway through the end of 2029 BOSTON and SAN DIEGO, November 4, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rappo" exhibit
Q3 FY2026 "Initial data from the open-label long-term safety trial in patients from the Phase 2a trial in FOS are expected in the fourth quarter of 2026." exhibit
Q3 FY2026 "Rapport plans to meet with the U.S. Food and Drug Administration (FDA) in the first quarter of 2027 to discuss the Phase 2 data and registrational trial design for RAP-219 in adults experiencing acute mania associated with BD, with initiation of two Phase 3 trials in acute bipolar mania expected in the second half of 2027." exhibit
Q3 FY2026 "Development of an LAI formulation of RAP-219 continues, with Phase 1 pharmacokinetic data expected in the third quarter of 2027." exhibit
Q3 FY2026 "The FDA has cleared the Company’s Investigational New Drug (IND) application for RAP-641, an α6β4 nicotinic acetylcholine receptor (nAChR) agonist, and the Company plans to initiate a Phase 1 clinical trial, with preliminary results expected in the second half of 2027." exhibit
Q2 FY2026 "RAP-219 Phase 2 trial in bipolar mania on track for topline results in October 2026 Pipeline continues to advance, including the RAP-219 long-acting injectable and primary generalized tonic-clonic seizures program, and the RAP-641 α6β4 nAChR program in chronic pain and migraine Ended the second quarter of 2026 with $436.1 million in cash, cash equivalents and short-term investments, excluding restricted cash, expected to fund operations into the second half of 2029 BOSTON and SAN DIEGO, August 5, 2026 – Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage" exhibit
Q2 FY2026 "China National Medical Products Administration (NMPA) approved the Investigational New Drug (IND) application for RAP-219 Phase 3 trials in FOS; Tenacia expects patient recruitment in China to begin in 4Q 2026." exhibit
Q2 FY2026 "The majority of patients from the RAP-219 Phase 2 trial in FOS have now enrolled in the open-label long term safety trial, with initial data expected in the fourth quarter of 2026." exhibit
Q2 FY2026 "The Phase 2 trial continues to progress, with topline results expected in October 2026." exhibit
Q2 FY2026 "IND-enabling activities for RAP-219's long-acting injectable formulation continue, with initial Phase 1 pharmacokinetic data expected in 2027. · RAP-641 α6β4 Program Continues to Progress Toward IND Submission." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/RAPP
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/RAPP

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

RAPP earnings date badge

HTML

<a href="https://veritasdata.dev/company/RAPP/"><img src="https://veritasdata.dev/embed/RAPP.svg" alt="RAPP earnings date" width="240" height="56"></a>

Markdown

[![RAPP earnings date](https://veritasdata.dev/embed/RAPP.svg)](https://veritasdata.dev/company/RAPP/)

Script

<script async src="https://veritasdata.dev/embed/RAPP.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/RAPP"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.